Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | The role of transplant in CTCL

Julia Jane Scarisbrick • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, gives an overview of the role of transplantation in the treatment of patients with cutaneous T-cell lymphoma (CTCL), talking on how it can prolong survival. Prof. Scarisbrick discusses the practicalities of transplantation in clinical practice, describing the use of reduced-intensity conditioning following the Stanford protocol, which combines total skin electron beam (TSEB), total nodal irradiation and ATG. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Julia Jane Scarisbrick

0:59
PROCLIPI: identification of key prognostic factors in CTCL
Julia Jane Scarisbrick • 15 Oct 2021
0:59
MAVORIC: mogamulizumab improves PFS for CTCL
Julia Jane Scarisbrick • 15 Oct 2021
0:46
ALCANZA: brentuximab vedotin improves ORR and PFS in CTCL
Julia Jane Scarisbrick • 15 Oct 2021
0:53
Maintenance therapy in CTCL
Julia Jane Scarisbrick • 15 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals